RNAC
Cartesian Therapeutics, Inc.
Key Financials
Net Income
$-130302000
↓ 68.3%
Operating Income
$-143405000
↓ 226.7%
Revenue
$2.8M
↓ 92.8%
Total Liabilities
$422.7M
↓ 4.3%
Total Assets
$296.4M
↓ 31.9%
Shareholders' Equity
$-126240000.00
↓ 1755.9%
EPS (Diluted)
$-5.02
↓ 11.8%
Operating Cash Flow
$-73941000.00
↓ 212.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 8-K | 6/17/2026 | View on SEC |
| 144 | 6/9/2026 | View on SEC |
| 8-K | 6/9/2026 | View on SEC |
| 144 | 6/2/2026 | View on SEC |
| 8-K | 5/26/2026 | View on SEC |
| SCHEDULE 13G/A | 5/6/2026 | View on SEC |
| S-8 | 4/30/2026 | View on SEC |
| 10-Q | 4/30/2026 | View on SEC |
| 8-K | 4/30/2026 | View on SEC |
| DEF 14A | 4/28/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | RNAC |
| Company Name | Cartesian Therapeutics, Inc. |
| CIK | 1453687 |
| Sector | Pharmaceutical Preparations |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 301-348-8698 |